Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Association Between p53 codon 72 Polymorphism and Cervical Cancer Risk Among Asians: a Huge Review and Meta-analysis

  • Zhou, Xin (Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University) ;
  • Gu, Yang (Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University) ;
  • Zhang, Shu-Lan (Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University)
  • Published : 2012.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: The aim of this Human Genome Epidemiology (HuGE) review and meta-analysis was to derive a more precise estimation of the association between p53 codon 72 polymorphism (Arg72Pro, rs1042522 G>C) and cervical cancer risk among Asians. Methods: A literature search of Pubmed, Embase, Web of Science and CBM databases from inception through June 2012 was conducted. The meta-analysis was performed using STATA 12.0 software. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of any association. Twenty-eight case-control studies were included with a total of 3,580 cervical cancer cases and 3,827 healthy controls. When all the eligible studies were pooled into the meta-analysis, the results showed that the Pro/Pro genotype was associated with increased risk of cervical cancer under the heterozygous model (Pro/Pro vs. Arg/Pro: OR = 1.25, 95%CI: 1.02-1.53, P= 0.005). However, no statistically significant associations were found under four other genetic models (Pro vs. Arg: OR = 0.97, 95%CI: 0.85-1.10, P= 0.624; Pro/Pro + Arg/Pro vs. Arg/Arg: OR = 0.84, 95%CI: 0.70-1.01, P= 0.058; Pro/Pro vs. Arg/Arg + Arg/Pro: OR = 1.13, 95%CI: 0.92-1.39, P= 0.242; Pro/Pro vs. Arg/Arg: OR = 0.97, 95%CI: 0.76-1.22, P= 0.765; respectively). In the subgroup analysis based on country, the Pro/Pro genotype and Pro carrier showed significant associations with increased risk of cervical cancer among Indian populations, but not among Chinese, Japanese and Korean populations. Conclusion: Results from the current meta-analysis suggests that p53 codon 72 polymorphism might be associated with increased risk of cervical cancer, especially among Indians.

Keywords

References

  1. Ashton KA, Proietto A, Otton G, et al (2009). Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol Oncol, 113, 109-14. https://doi.org/10.1016/j.ygyno.2008.12.036
  2. Baek WK, Cho JW, Suh SI, et al (2000). p53 codon 72 polymorphism and risk of cervical carcinoma in Korean women. J Korean Med Sci, 15, 65-7. https://doi.org/10.3346/jkms.2000.15.1.65
  3. Berchuck A, Kohler MF, Marks JR, et al (1994). The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol, 170, 246-52. https://doi.org/10.1016/S0002-9378(94)70414-7
  4. Bhattacharya P, Duttagupta C, Sengupta S (2002). Proline homozygosity in codon 72 of p53: a risk genotype for human papillomavirus related cervical cancer in Indian women. Cancer Lett, 188, 207-11. https://doi.org/10.1016/S0304-3835(02)00430-5
  5. Cho NH, Lim SY, Kim YT, et al (2003). G2 checkpoint in uterine cervical cancer with HPV 16 E6 according to p53 polymorphism and its screening value. Gynecol Oncol, 90, 15-22. https://doi.org/10.1016/S0090-8258(03)00198-7
  6. Fan R, Wu MT, Miller D, et al (2000). The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev, 9, 1037-42.
  7. Grochola LF, Zeron-Medina J, Meriaux S, et al (2010). Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb Perspect Biol, 2, a001032. https://doi.org/10.1101/cshperspect.a001032
  8. Harris CC, Hollstein M (1993). Clinical implications of the p53 tumor-suppressor gene. N Engl J Med, 329, 1318-27. https://doi.org/10.1056/NEJM199310283291807
  9. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. https://doi.org/10.1002/sim.1186
  10. Hou MM, Xi MR, Cao ZY, et al (2006). P53 codon 72 polymorphism in cervical cancers and its correlation with HPV16,18E6. Sichuan Da Xue Xue Bao Yi Xue Ban, 37, 404-7.
  11. Jemal A, Siegel R, Xu J, et al (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. https://doi.org/10.3322/caac.20073
  12. Katiyar S, Thelma BK, Murthy NS, et al (2003). Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Mol Cell Biochem, 252, 117-24. https://doi.org/10.1023/A:1025546610920
  13. Kawamata Y, Mitsuhashi A, Unno Y, et al (2002). HPV 16-E6-mediated degradation of intrinsic p53 is compensated by upregulation of p53 gene expression in normal cervical keratinocytes. Int J Oncol, 21, 561-7.
  14. Kim JW, Lee CG, Park YG, et al (2000). Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and CYP2E1: relation to the incidence rate of cervical carcinoma. Cancer, 88, 2082-91. https://doi.org/10.1002/(SICI)1097-0142(20000501)88:9<2082::AID-CNCR14>3.0.CO;2-D
  15. Kim JW, Roh JW, Park NH, et al (2001). Polymorphism of TP53 codon 72 and the risk of cervical cancer among Korean women. Am J Obstet Gynecol, 184, 55-8. https://doi.org/10.1067/mob.2001.108329
  16. Koushik A, Platt RW, Franco EL (2004). p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev, 13, 11-22. https://doi.org/10.1158/1055-9965.EPI-083-3
  17. Lax SF (2004). Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecularbased classification. Virchows Arch, 444, 213-23. https://doi.org/10.1007/s00428-003-0947-3
  18. Lee JE, Lee SJ, Namkoong SE, et al (2004). Gene-gene and gene-environmental interactions of p53, p21, and IRF-1 polymorphisms in Korean women with cervix cancer. Int J Gynecol Cancer, 14, 118-25. https://doi.org/10.1111/j.1048-891x.2004.014040.x
  19. Li CY, Liu JH, Huang BJ (2004). Correlation between P53 codon 72 polymorphism and tumorigenesis of cervical cancer. Ai Zheng, 23, 1396-9.
  20. Minaguchi T, Kanamori Y, Matsushima M, et al (1998). No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection. Cancer Res, 58, 4585-6.
  21. Mitra S, Misra C, Singh RK, et al (2005). Association of specific genotype and haplotype of p53 gene with cervical cancer in India. J Clin Pathol, 58, 26-31. https://doi.org/10.1136/jcp.2004.019315
  22. Nagpal JK, Sahni S, Das BR (2002). P53 codon 72 polymorphism and susceptibility to development of human papilloma virusassociated cervical cancer in Indian women. Eur J Clin Invest, 32, 943-8. https://doi.org/10.1046/j.1365-2362.2002.01096.x
  23. Ngan HY, Liu VW, Liu SS (1999). Risk of cervical cancer is not increased in Chinese carrying homozygous arginine at codon 72 of p53. Br J Cancer, 80, 1828-9. https://doi.org/10.1038/sj.bjc.6690606
  24. Niwa Y, Hamajima N, Atsuta Y, et al (2004). Genetic polymorphisms of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro and the risk of cervical cancer in Japanese. Cancer Lett, 205, 55-60. https://doi.org/10.1016/j.canlet.2003.11.014
  25. Nunobiki O, Ueda M, Yamamoto M, et al (2009). Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer. Hum Cell, 22, 101-6. https://doi.org/10.1111/j.1749-0774.2009.00075.x
  26. Ozalp S, Yalcin OT, Tanir HM, et al (2003). p53 overexpression as a prognostic indicator in endometrial carcinoma. Eur J Gynaecol Oncol, 24, 275-8.
  27. Pecorelli S, Favalli G, Zigliani L, et al (2003). Cancer in women. Int J Gynaecol Obstet, 82, 369-79. https://doi.org/10.1016/S0020-7292(03)00225-X
  28. Peters JL, Sutton AJ, Jones DR, et al (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA, 295, 676-80. https://doi.org/10.1001/jama.295.6.676
  29. Qie M, Zhang Y and Wu J (2002). Study on the relationship between cervical cancer and p53 codon 72 polymorphism. Hua Xi Yi Ke Da Xue Xue Bao, 33, 274-5.
  30. Risinger JI, Dent GA, Ignar-Trowbridge D, et al (1992). p53 gene mutations in human endometrial carcinoma. Mol Carcinog, 5, 250-3. https://doi.org/10.1002/mc.2940050403
  31. Roh JW, Kim JW, Park NH, et al (2004). p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol Oncol, 93, 499-505. https://doi.org/10.1016/j.ygyno.2004.02.005
  32. Saranath D, Khan Z, Tandle AT, et al (2002). HPV16/18 prevalence in cervical lesions/cancers and p53 genotypes in cervical cancer patients from India. Gynecol Oncol, 86, 157-62. https://doi.org/10.1006/gyno.2002.6735
  33. Settheetham-Ishida W, Singto Y, Yuenyao P, et al (2004). Contribution of epigenetic risk factors but not p53 condon72 polymorphism to the development of cervical cancer in Northeastern Thailand. Cancer Lett, 2, 205-11.
  34. Sherman ME (2000). Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol, 13, 295-308. https://doi.org/10.1038/modpathol.3880051
  35. Soliman PT, Oh JC, Schmeler KM, et al (2005). Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol, 105, 575-80. https://doi.org/10.1097/01.AOG.0000154151.14516.f7
  36. Ueda M, Terai Y, Kanda K, et al (2006). Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol Oncol, 100, 173-8. https://doi.org/10.1016/j.ygyno.2005.08.015
  37. Wang XL, Pan XL, Zheng XZ, et al (2004). Correlation between P53 Condon72 polymorphism and cervical carcinoma among Uigur and Han People. J Shihezi University, 4, 340-4.
  38. Whibley C, Pharoah PD and Hollstein M (2009). p53 polymorphisms: cancer implications. Nat Rev Cancer, 9, 95-107. https://doi.org/10.1038/nrc2584
  39. Wu MT, Liu CL, Ho CK, et al (2004). Genetic polymorphism of p53 and XRCC1 in cervical intraepithelial neoplasm in Taiwanese women. J Formos Med Assoc, 103, 337-43.
  40. Yamashita T, Yaginuma Y, Saitoh Y, et al (1999). Codon 72 polymorphism of p53 as a risk factor for patients with human papillomavirus-associated squamous intraepithelial lesions and invasive cancer of the uterine cervix. Carcinogenesis, 20, 1733-6. https://doi.org/10.1093/carcin/20.9.1733
  41. Yang A, Zheng X, Tao L, et al (2008). Studies on correlation between p21Ser31Arg, p53arg72Pro polymorphisms and cervical carcinoma in Uigur women in Xinjiang. J Shihezi University, 1, 6-11.
  42. Yang HP, Gonzalez Bosquet J, Li Q, et al (2010). Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes. Carcinogenesis, 31, 827-33. https://doi.org/10.1093/carcin/bgp328
  43. Yang YC, Chang CL, Chen ML (2001). Effect of p53 polymorphism on the susceptibility of cervical cancer. Gynecol Obstet Invest, 51, 197-201. https://doi.org/10.1159/000052924
  44. Yao N, Zeng H, Lu J (2008). Correlation between p53 condon72 polymorphism and cervical cancer. Acta Academiae Zunyi, 1, 3-5.
  45. Ye S (2000). Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol, 19, 623-9. https://doi.org/10.1016/S0945-053X(00)00102-5
  46. Zheng XZ, Yang AQ, Pan XL, et al (2008). Ethnicity determines association of p53Arg72Pro alleles with cervical cancer in China. Eur J Cancer Prev, 17, 460-6. https://doi.org/10.1097/CEJ.0b013e3282f75f3e
  47. Zheng XZ, Yang AQ, Pan XL, et al (2007). Relationship between p53 Arg72Pro polymorphism and cervical carcinoma in Uigur and Han women in Xinjiang. Zhonghua Bing Li Xue Za Zhi, 36, 511-5.
  48. Zhou X, Han S, Wang S, et al (2009). Polymorphisms in HPV E6/E7 protein interacted genes and risk of cervical cancer in Chinese women: a case-control analysis. Gynecol Oncol, 114, 327-31. https://doi.org/10.1016/j.ygyno.2009.05.011
  49. Zintzaras E and Ioannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol, 28, 123-37. https://doi.org/10.1002/gepi.20048
  50. Zubor P, Stanclova A, Kajo K, et al (2009). The p53 codon 72 exon 4 BstUI polymorphism and endometrial cancer in Caucasian women. Oncology, 76, 173-83. https://doi.org/10.1159/000201570
  51. Zucchetto A, Serraino D, Polesel J, et al (2009). Hormonerelated factors and gynecological conditions in relation to endometrial cancer risk. Eur J Cancer Prev, 18, 316-21. https://doi.org/10.1097/CEJ.0b013e328329d830

Cited by

  1. Associations of TP53 mutations, codon 72 polymorphism and human papillomavirus in head and neck squamous cell carcinoma patients vol.30, pp.6, 2013, https://doi.org/10.3892/or.2013.2750
  2. Association between the TP53 codon 72 polymorphism and risk of oral squamous cell carcinoma in Asians: a meta-analysis vol.14, pp.1, 2014, https://doi.org/10.1186/1471-2407-14-469
  3. Cervical Cancer Gene Therapy by Gene Loaded PEG-PLA Nanomedicine vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.4915
  4. Association of a miR-502-Binding Site Single Nucleotide Polymorphism in the 3'-Untranslated Region of SET8 and the TP53 Codon 72 Polymorphism with Cervical Cancer in the Chinese Population vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6505
  5. Stratification Analysis and Case-control Study of Relationships between Interleukin-6 Gene Polymorphisms and Cervical Cancer Risk in a Chinese Population vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7357
  6. Impact of Caspase-8 (CASP8) -652 6N Del and D302H Polymorphisms on Prostate Cancer in Different Ethnic Groups vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7713
  7. Analysis of TP53 Polymorphisms in North Indian Sporadic Esophageal Cancer Patients vol.15, pp.19, 2014, https://doi.org/10.7314/APJCP.2014.15.19.8413
  8. Reversal of Resistance towards Cisplatin by Curcumin in Cervical Cancer Cells vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1403
  9. Pathways and Delayed Cyclin B1 Nuclear Translocation vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.4101
  10. CCND1 G870A polymorphism contributes to the risk of esophageal cancer: An updated systematic review and cumulative meta-analysis vol.2, pp.4, 2014, https://doi.org/10.3892/br.2014.286
  11. No Evidence of Association of the Arg72Pro p53 Gene Polymorphism with Cancer Risk in the Saudi Population: a Meta-Analysis vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5663
  12. P53 Polymorphism at Codon 72 is Associated with Keratocystic Odontogenic Tumors in the Thai Population vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1997
  13. Lack of Influence of TP53 Arg72Pro and 16bp Duplication Polymorphisms on Risk of Breast Cancer in Iran vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2971
  14. Update knowledge on cervical cancer incidence and prevalence in Asia vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3617
  15. Genetic susceptibility to cervical cancer: role of common polymorphisms in apoptosis-related genes vol.36, pp.9, 2015, https://doi.org/10.1007/s13277-015-3868-2
  16. Curcumin improves the paclitaxel-induced apoptosis of HPV-positive human cervical cancer cells via the NF-κB-p53-caspase-3 pathway vol.9, pp.4, 2015, https://doi.org/10.3892/etm.2015.2240
  17. Co-expression of ING4 and P53 enhances hypopharyngeal cancer chemosensitivity to cisplatin in vivo vol.14, pp.3, 2016, https://doi.org/10.3892/mmr.2016.5552
  18. The potential role of infectious agents and pelvic inflammatory disease in ovarian carcinogenesis vol.12, pp.1, 2017, https://doi.org/10.1186/s13027-017-0134-9
  19. Association of codon 72 polymorphism of p53 with the severity of cervical dysplasia, E6-T350G and HPV16 variant lineages in HPV16-infected women vol.66, pp.9, 2017, https://doi.org/10.1099/jmm.0.000563
  20. Genetic Susceptibility for Cervical Cancer in African Populations: What Are the Host Genetic Drivers? vol.22, pp.7, 2018, https://doi.org/10.1089/omi.2018.0075